On August 19, Amgen rose 3.05% in regular trading, trading at $438.96/share, with turnover of $123 million. Multiple analyst target price upgrades and broad biotech sector momentum drove the stock higher.

Morgan Stanley raised its price target on Amgen from $351 to $362 while maintaining an Equalweight rating. Mizuho also raised its target to $352 the same day. According to FactSet, analysts maintain an average Overweight rating with a mean target of $390.15. These upgrades follow Amgen's strong Q2 results reported earlier this month, with adjusted EPS of $6.29 beating the $5.62 consensus by approximately 12%, and revenue of $10.05 billion rising 9.5% year-over-year. The company raised full-year guidance to adjusted EPS of $22.30-$23.50 on revenue of $38.2-$39.4 billion, both above prior estimates.

Within the Biotechnology sector, notable gains included Moderna up 111.58%, BioNTech up 19.36%, Gilead Sciences up 3.11%, and AbbVie up 2.19%, reflecting broad sector strength.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)